Microencapsulation of Clostridium difficile specific bacteriophages using microfluidic glass capillary devices for colon delivery using pH triggered release

PLoS ONE

Volumn 12, Issue 10, 2017, Pages

  Vinner, Gurinder K ^a   Vladisavljević, Goran T ^a   Clokie, Martha R J ^b   Malik, Danish J ^a  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOIC ACID; ALGINIC ACID; ANTIINFECTIVE AGENT; CLOSTRIDIUM DIFFICILE PHAGE CDKM9; EUDRAGIT; OIL; UNCLASSIFIED DRUG;

ARTICLE; BACTERIOPHAGE; COLON; CONTROLLED STUDY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; FLOW RATE; INTESTINE; MICROENCAPSULATION; MICROFLUIDIC GLASS CAPILLARY DEVICE; NONHUMAN; PARTICLE SIZE; PEPTOCLOSTRIDIUM DIFFICILE; PH; PHYSICAL PHASE; SIMULATION; STOMACH PH; CHEMISTRY; HUMAN; LAB ON A CHIP; MICROBIOLOGY; MYOVIRIDAE; PHAGE THERAPY; PROCEDURES; PSEUDOMEMBRANOUS COLITIS; VIROLOGY;

CLOSTRIDIUM DIFFICILE; COLON; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; HYDROGEN-ION CONCENTRATION; LAB-ON-A-CHIP DEVICES; MYOVIRIDAE; PARTICLE SIZE; PHAGE THERAPY;

EID: 85031106066     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0186239     Document Type: Article

References (97)

1. Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens H, Holmes A. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. 2013;1–13.
2. Freire-moran L, Aronsson B, Manz C, Gyssens IC, So AD, Monnet DL, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria—Time to react is now. Drug Resist Updat. 2011; 14(2):118–24. https://doi.org/10.1016/j.drup.2011.02.003 PMID: 21435939
3. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, et al. Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis. 2016; 16:239–51. https://doi.org/10.1016/S1473-3099(15) 00466-1 PMID: 26795692
4. Alisky J, Iczkowski K, Rapoport a, Troitsky N. Bacteriophages show promise as antimicrobial agents. J Infect. 1998; 36(1):5–15. PMID: 9515662
5. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage. 2011 Jan; 1(2):66–85. https://doi.org/10.4161/bact.1.2.15845 PMID: 22334863
6. Allen HK, Trachsel J, Looft T, Casey T a. Finding alternatives to antibiotics. Ann N Y Acad Sci. 2014 Sep; 1323:91–100. https://doi.org/10.1111/nyas.12468 PMID: 24953233
7. Abedon ST. Kinetics of phage-mediated biocontrol of bacteria. Foodborne Pathog Dis. 2009; 6(7):807–15. https://doi.org/10.1089/fpd.2008.0242 PMID: 19459758
8. Summers WC. Bacteriophage Therapy. Annu Rev Microbiol. 2001; 55:437–51. https://doi.org/10.1146/annurev.micro.55.1.437 PMID: 11544363
9. Lu TK, Koeris MS. The next generation of bacteriophage therapy. Curr Opin Microbiol. 2011 Oct; 14 (5):524–31. https://doi.org/10.1016/j.mib.2011.07.028 PMID: 21868281
10. Housby JN, Mann NH. Phage therapy. Drug Discov Today. 2009; 14(11–12):536–40. https://doi.org/10.1016/j.drudis.2009.03.006 PMID: 19508915
11. Levin BR, Bull JJ. Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol. 2004; 2 (2):166–73. https://doi.org/10.1038/nrmicro822 PMID: 15040264
12. Cairns BJ, Timms AR, Jansen VAA, Connerton IF, Payne RJH. Quantitative models of in vitro bacteriophage-host dynamics and their application to phage therapy. PLoS Pathog. 2009; 5(1):1–10.
13. Bruttin A, Bru H. Human Volunteers Receiving Escherichia coli Phage T4 Orally: a Safety Test of Phage Therapy. 2005; 49(7):2874–8. https://doi.org/10.1128/AAC.49.7.2874-2878.2005 PMID: 15980363
14. Sarker SA, Sultana S, Reuteler G, Moine D, Descombes P, Charton F, et al. Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. EBioMedicine. 2016; 4:124–37. https://doi.org/10.1016/j.ebiom.2015.12.023 PMID: 26981577
15. Connerton PL, Timms a. R, Connerton IF. Campylobacter bacteriophages and bacteriophage therapy. J Appl Microbiol. 2011; 111(2):255–65. https://doi.org/10.1111/j.1365-2672.2011.05012.x PMID: 21447013
16. Abedon ST. Ecology of anti-biofilm agents I: Antibiotics versus bacteriophages. Pharmaceuticals. 2015; 8(3):525–58. https://doi.org/10.3390/ph8030525 PMID: 26371010
17. Nale JY, Chutia M, Carr P, Hickenbotham PT, Clokie MRJ. “Get in Early”; Biofilm and Wax Moth (Galleria mellonella) Models Reveal New Insights into the Therapeutic Potential of Clostridium difficile Bacteriophages. Front Microbiol. 2016; 7(August):1–16.
18. Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR, et al. Quality and safety requirements for sustainable phage therapy products. Pharm Res. 2015; 32(7):2173–9. https://doi.org/10.1007/s11095-014-1617-7 PMID: 25585954
19. Schmelcher M, Loessner MJ. Application of bacteriophages for detection of foodborne pathogens. Bacteriophage. 2014; 4(1):e28137. https://doi.org/10.4161/bact.28137 PMID: 24533229
20. Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 1997; 5(7):268–71. https://doi.org/10.1016/S0966-842X(97)01054-8PMID: 9234508
21. Galtier M, De Sordi L, Maura D, Arachchi H, Volant S, Dillies MA, et al. Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low impact on microbiota composition. Environ Microbiol. 2016; 18(7):2237–45. https://doi.org/10.1111/1462-2920.13284 PMID: 26971586
22. Viswanathan VK, Hodges K, Hecht G. Enteric infection meets intestinal function: how bacterial pathogens cause diarrhoea. Nat Rev Microbiol. 2009; 7(2):110–9. https://doi.org/10.1038/nrmicro2053PMID: 19116615
23. Burke KE, Lamont JT. Clostridium difficile infection: A worldwide disease. Gut Liver. 2014; 8(1):1–6. https://doi.org/10.5009/gnl.2014.8.1.1 PMID: 24516694
24. He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Melissa J, et al. Europe PMC Funders Group Emergence and global spread of epidemic healthcare-associated Clostridium difficile. 2013; 45(1):109–13.
25. Bouza E. Consequences of Clostridium difficile infection: Understanding the healthcare burden. Clin Microbiol Infect. 2012; 18(SUPPL.6):5–12.
26. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol [Internet]. 2009 Jul [cited 2013 Jan 30]; 7(7):526–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19528959 https://doi.org/10.1038/nrmicro2164 PMID: 19528959
27. Vardakas KZ, Polyzos K a., Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: A systematic review of the evidence. Int J Antimicrob Agents. 2012; 40(1):1–8. https://doi.org/10.1016/j.ijantimicag.2012.01.004 PMID: 22398198
28. Nale JY, Spencer J, Hargreaves KR, Buckley AM, Trzepin P, Douce GR, et al. Bacteriophage Combinations Significantly Reduce Clostridium difficile Growth In Vitro and Proliferation In Vivo. Antimicrob Agents Chemother. 2016; 60(2):968–81. https://doi.org/10.1128/AAC.01774-15 PMID: 26643348
29. Young R, Gill JJ. Phage therapy redux—What is to be done? Science (80-). 2015; 350(6265):1163–4.
30. Choinska-Pulit A, Mitula P, Sliwka P, Choi A, Wojciech Ł, Skaradzinska A. Bacteriophage encapsulation: Trends and potential applications a. Trends Food Sci Technol. 2015; 45:212–21.
31. Ma Y, Pacan JC, Wang Q, Xu Y, Huang X, Korenevsky A, et al. Microencapsulation of Bacteriophage Felix O1 into Chitosan-Alginate Microspheres for Oral Delivery. Appl Environ Microbiol. 2008; 74 (15):4799–805. https://doi.org/10.1128/AEM.00246-08 PMID: 18515488
32. Tang Z, Huang X, Baxi S, Chambers JR, Sabour PM, Wang Q. Whey protein improves survival and release characteristics of bacteriophage Felix O1 encapsulated in alginate microspheres. Food Res Int. 2013 Jul; 52(2):460–6.
33. Kim S, Jo A, Ahn J. Application of chitosan-alginate microspheres for the sustained release of bacteriophage in simulated gastrointestinal conditions. Int J Food Sci Technol. 2015; 50(4):913–8.
34. Merabishvili M, Vervaet C, Pirnay JP, de Vos D, Verbeken G, Mast J, et al. Stability of Staphylococcus aureus Phage ISP after Freeze-Drying (Lyophilization). PLoS One. 2013; 8(7):1–7.
35. Lee SW, Belcher AM. Virus-based fabrication of micro- and nanofibers using electrospinning. Nano Lett. 2004; 4(3):387–90.
36. Puapermpoonsiri U, Spencer J, Walle CF Van Der. A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. Eur J Pharm Biopharm. 2009; 72:26–33. https://doi.org/10.1016/j.ejpb.2008.12.001 PMID: 19118627
37. Ma Y, Pacan JC, Wang Q, Sabour PM, Huang X, Xu Y. Enhanced alginate microspheres as means of oral delivery of bacteriophage for reducing Staphylococcus aureus intestinal carriage. Food Hydrocoll [Internet]. 2012 Mar [cited 2014 Apr 9]; 26(2):434–40. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0268005X10002729
38. Shi LE, Zheng W, Zhang Y, Tang ZX. Milk-alginate microspheres: Protection and delivery of Enterococcus faecalis HZNU P2. LWT—Food Sci Technol. 2016; 65:840–4.
39. Puapermpoonsiri U, Spencer J, Walle CF Van Der. A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. Eur J Pharm Biopharm [Internet]. 2009; 72(1):26–33. Available from: http://dx.doi.org/10.1016/j.ejpb.2008.12.001 https://doi.org/10.1016/j.ejpb.2008.12.001 PMID: 19118627
40. Brouzes E, Medkova M, Savenelli N, Marran D, Twardowski M, Hutchison JB, et al. Droplet microfluidic technology for single-cell high-throughput screening. Proc Natl Acad Sci U S A. 2009; 106(34):14195–200. https://doi.org/10.1073/pnas.0903542106 PMID: 19617544
41. Chen S, Guo F, Deng T, Zhu S, Liu W, Zhong H, et al. Eudragit S100-Coated Chitosan Nanoparticles Co-loading Tat for Enhanced Oral Colon Absorption of Insulin. AAPS PharmSciTech. 2016;1–11.
42. Lee KT, Mooney DJ. Alginate: properties and biomedical applications. Polym Sci. 2013; 37(1):106–26.
43. Nguyen DA, Fogler HS. Facilitated diffusion in the dissolution of carboxylic polymers. AIChE J. 2005 Feb; 51(2):415–25.
44. Duan H, Lü S, Gao C, Bai X, Qin H, Wei Y, et al. Mucoadhesive microparticulates based on polysaccharide for target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colon. Colloids Surfaces B Biointerfaces. 2016; 145:510–9. https://doi.org/10.1016/j.colsurfb.2016.05.038 PMID: 27239905
45. Sookkasem A, Chatpun S, Yuenyongsawad S, Wiwattanapatapee R. Alginate beads for colon specific delivery of self-emulsifying curcumin. J Drug Deliv Sci Technol. 2015; 29:159–66.
46. Vemula SK, Veerareddy PR, Devadasu VR. Pharmacokinetics of colon-specific pH and time-dependent flurbiprofen tablets. Eur J Drug Metab Pharmacokinet. 2015; 40(3):301–11. https://doi.org/10.1007/ s13318-014-0210-0 PMID: 24916715
47. Vladisavljević GT, Kobayashi I, Nakajima M. Production of uniform droplets using membrane, micro-channel and microfluidic emulsification devices. Microfluid Nanofluidics [Internet]. 2012 Feb 18 [cited 2014 Sep 25]; 13(1):151–78. Available from: http://link.springer.com/10.1007/s10404-012-0948-0
48. Rashid S, Barylski J, Hargreaves K, Millard A, Vinner G, Clokie M. Two Novel Myoviruses from the North of Iraq Reveal Insights into Clostridium difficile Phage Diversity and Biology. Viruses. 2016; 8:1–18.
49. Mahony DE, Bell PD, Easterbrook KB. Two Bacteriophages of Clostridium difficile. J Clin Microbiol. 1985; 21(2):251–4. PMID: 3972994
50. Goh S, Chang BJ, Riley T V. Effect of phage infection on toxin production by Clostridium difficile. J Med Microbiol. 2005; 54(2):129–35.
51. Ibekwe VC, Fadda HM, McConnell EL, Khela MK, Evans DF, Basit AW. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res. 2008; 25(8):1828–35. https://doi.org/10.1007/s11095-008-9580-9 PMID: 18465212
52. Utada AS, Fernandez-Nieves A, Stone H a., Weitz D a. Dripping to jetting transitions in coflowing liquid streams. Phys Rev Lett. 2007; 99(9):1–4.
53. Erb RM, Obrist D, Chen PW, Studer J, Studart AR. Predicting sizes of droplets made by microfluidic flow-induced dripping. Soft Matter. 2011; 7(19):8757.
54. Fu T, Wu Y, Ma Y, Li HZ. Droplet formation and breakup dynamics in microfluidic flow-focusing devices: From dripping to jetting. Chem Eng Sci. 2012; 84:207–17.
55. Ekanem EE, Nabavi SA, Vladisavljevic GT, Gu S. Structured Biodegradable Polymeric Microparticles for Drug Delivery Produced Using Flow Focusing Glass Microfluidic Devices. ACS Appl Mater Interfaces. 2015; 7(41):23132–43. https://doi.org/10.1021/acsami.5b06943 PMID: 26423218
56. Vladisavljević GT, Duncanson WJ, Shum HC, Weitz D a. Emulsion templating of poly(lactic acid) particles: Droplet formation behavior. Langmuir. 2012; 28(36):12948–54. https://doi.org/10.1021/la302092fPMID: 22860633
57. Seo M, Paquet C, Nie Z, Xu S, Kumacheva E. Microfluidic consecutive flow-focusing droplet generators. Soft Matter. 2007; 3(8):986.
58. Leibo SP, Mazur P. Effect of Osmotic Shock and Low Salt Concentration on Survival and Density of Bacteriophages T4B and T4Bo1. Biophys J. 1966; 6(6):747–72. https://doi.org/10.1016/S0006-3495 (66)86693-6 PMID: 5972376
59. Huang S, Yang H, Lakshmanan RS, Johnson ML, Chen I, Wan J, et al. The effect of salt and phage concentrations on the binding sensitivity of magnetoelastic biosensors for Bacillus anthracis detection. Biotechnol Bioeng. 2008; 101(5):1014–21. https://doi.org/10.1002/bit.21995 PMID: 18563848
60. Samtlebe M, Ergin F, Wagner N, Neve H, Küçükçetin A, Franz CMAP, et al. Carrier systems for bacteriophages to supplement food systems: Encapsulation and controlled release to modulate the human gut microbiota. LWT—Food Sci Technol. 2016; 68:334–40.
61. Tang Z, Huang X, Sabour PM, Chambers JR, Wang Q. Preparation and characterization of dry powder bacteriophage K for intestinal delivery through oral administration. LWT—Food Sci Technol [Internet]. 2015; 60(1):263–70. Available from: http://dx.doi.org/10.1016/j.lwt.2014.08.012
62. Dini C, Islan GA, de Urraza PJ, Castro GR. Novel Biopolymer Matrices for Microencapsulation of Phages: Enhanced Protection Against Acidity and Protease Activity. Macromol Biosci. 2012; 12:1200–8. https://doi.org/10.1002/mabi.201200109 PMID: 22847825
63. Colom J, Cano-Sarabia M, Otero J, Aríñez-Soriano J, Cortés P, Maspoch D, et al. Microencapsulation with alginate/CaCO3: A strategy for improved phage therapy. Sci Rep [Internet]. 2017; 7(January):41441. Available from: http://www.nature.com/articles/srep41441
64. Wall SK, Zhang J, Rostagno MH, Ebner PD. Phage therapy to reduce preprocessing Salmonella infections in market-weight swine. Appl Environ Microbiol. 2010; 76(1):48–53. https://doi.org/10.1128/AEM. 00785-09 PMID: 19854929
65. Stillwell MT, Holdich RG, Kosvintsev SR, Gasparini G, Cumming IW. Stirred cell membrane emulsification and factors influencing dispersion drop size and uniformity. Ind Eng Chem Res. 2007; 46(3):965–72.
66. Egidi E, Gasparini G, Holdich RG, Vladisavljević GT, Kosvintsev SR. Membrane emulsification using membranes of regular pore spacing: Droplet size and uniformity in the presence of surface shear. J Memb Sci. 2008; 323(2):414–20.
67. Jain D, Panda AK, Majumdar DK. Eudragit S100 entrapped insulin microspheres for oral delivery. AAPS PharmSciTech. 2005 Jan; 6(1):E100–7. https://doi.org/10.1208/pt060116 PMID: 16353953
68. Surh J., Mun S., McClements DJ. Preparation and Characterization of Water / Oil and Water / Oil / Water Emulsions Containing Biopolymer-Gelled Water Droplets. J Agric Food Chem. 2007; 55(1):175–84. https://doi.org/10.1021/jf061637q PMID: 17199330
69. Sağlam D, Venema P, de Vries R, Sagis LMC, van der Linden E. Preparation of high protein micro-particles using two-step emulsification. Food Hydrocoll. 2011 Jul; 25(5):1139–48.
70. Kong T, Wu J, To M, Wai Kwok Yeung K, Cheung Shum H, Wang L. Droplet based microfluidic fabrication of designer microparticles for encapsulation applications. Biomicrofluidics. 2012; 6(3): https://doi.org/10.1063/1.4738586 PMID: 23874367
71. Leung SSY, Parumasivam T, Gao FG, Carrigy NB, Vehring R, Finlay WH, et al. Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections. Pharm Res. 2016; 33(6):1486–96. https://doi.org/10.1007/s11095-016-1892-6 PMID: 26928668
72. Vandenheuvel D, Singh A, Vandersteegen K, Klumpp J, Lavigne R, Van Den Mooter G. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections. Eur J Pharm Biopharm [Internet]. 2013; 84(3):578–82. Available from: http://dx.doi.org/10.1016/j.ejpb.2012.12.022 https://doi.org/10.1016/j.ejpb.2012.12.022 PMID: 23353012
73. Briers Y, Miroshnikov K, Chertkov O, Nekrasov A, Mesyanzhinov V, Volckaert G, et al. The structural peptidoglycan hydrolase gp181 of bacteriophage phiKZ. Biochem Biophys Res Commun. 2008; 374 (4):747–51. https://doi.org/10.1016/j.bbrc.2008.07.102 PMID: 18671939
74. Knezevic P, Obreht D, Curcin S, Petrusic M, Aleksic V, Kostanjsek R, et al. Phages of Pseudomonas aeruginosa: Response to environmental factors and in vitro ability to inhibit bacterial growth and biofilm formation. J Appl Microbiol. 2011; 111(1):245–54. https://doi.org/10.1111/j.1365-2672.2011.05043.xPMID: 21554503
75. McConnell EL, Fadda HM, Basit AW. Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm. 2008 Dec; 364(2):213–26. https://doi.org/10.1016/j.ijpharm.2008.05.012 PMID: 18602774
76. Davies JD, Kelly MJ. The preservation of bacteriophage H1 of Corynebacterium ulcerans U103 by freeze-drying. J Hyg (Lond). 1969; 67(4):573–83.
77. Governal R a, Gerba CP. Persistence of MS-2 and PRD-1 bacteriophages in an ultrapure water system. J Ind Microbiol Biotechnol. 1997; 18(5):297–301. PMID: 9218359
78. Jończyk E, Kłak M, Międzybrodzki R, Górski a. The influence of external factors on bacteriophages—review. Folia Microbiol (Praha). 2011; 56(3):191–200.
79. George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: Alginate and chitosan—a review. J Control Release. 2006; 114(1):1–14. https://doi.org/10.1016/j.jconrel.2006.04. 017 PMID: 16828914
80. Kim S, Jo A, Ahn J. Application of chitosan–alginate microspheres for the sustained release of bacteriophage in simulated gastrointestinal conditions. Int J Food Sci Technol. 2015; 50:913–8.
81. Smith, Williams; Huggins, Michael B.; Shaw KM; The Control of Experimental Escherichia coli Diar-rhoea in Calves by Means of Bacteriophages. J Gen Microbiol. 1987; 133:1111–26. https://doi.org/10.1099/00221287-133-5-1111 PMID: 3309177
82. Wills QF, Kerrigan C, Soothill JS. Experimental Bacteriophage Protection against Staphylococcus aureus Abscesses in a Rabbit Model Experimental Bacteriophage Protection against Staphylococcus aureus Abscesses in a Rabbit Model. Antimicrob Agents Chemother. 2005; 49(3):1220–1. https://doi.org/10.1128/AAC.49.3.1220-1221.2005 PMID: 15728933
83. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, et al. Bacteriophage Therapy Rescues Mice Bacteremic from a Clinical Isolate of Vancomycin-Resistant Enterococcus faecium. Infect Immun. 2002; 70(1):204–10. https://doi.org/10.1128/IAI.70.1.204-210.2002 PMID: 11748184
84. Cerveny KE., DePaola A., Duckworth DH., Gulig PA. Phage Therapy of Local and Systemic Disease Caused by Vibrio vulnificus in Iron-Dextran-Treated Mice. Infect Immun. 2002; 70(11):6251–62. https://doi.org/10.1128/IAI.70.11.6251-6262.2002 PMID: 12379704
85. Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol [Internet]. 1987; 133(5):1111–26. Available from: http://mic.microbiologyresearch.org/content/journal/micro/10.1099/00221287-133-5-1111\nhttp://www.ncbi.nlm.nih.gov/pubmed/3309177 https://doi.org/10.1099/00221287-133-5-1111 PMID: 3309177
86. Barrow P, Lovell M. Use of Lytic Bacteriophage for Control of Experimental Escherichia coli Septicemia and Meningitis in Chickens and Calves. Clin Diagn Lab Immunol. 1998; 5(3):294–8. PMID: 9605979
87. Chibani-chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Bru H. In Vitro and In Vivo Bacteriolytic Activities of Escherichia coli Phages: Implications for Phage Therapy. Antimicrob Agents Chemother. 2004; 48(7):2558–69. https://doi.org/10.1128/AAC.48.7.2558-2569.2004 PMID: 15215109
88. Abdulamir AS, Sabah J, BakarFatimah A. Novel approach of using a cocktail of designed bacteriophages against gut pathogenic E. coli for bacterial load biocontrol. Ann Clin Microbiol Antimicrob. 2014; 13(39):1–11.
89. Yen M, Cairns LS, Camilli A, Zuckerman JN, Rombo L, Fisch A, et al. A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models. Nat Commun [Internet]. 2017; 8:14187. Available from: http://www.nature.com/doifinder/10.1038/ncomms14187 https://doi.org/10.1038/ ncomms14187 PMID: 28146150
90. Stanford K, Niu YD, Johnson R. Oral delivery systems for encapsulated bacteriophages targeted at Escherichia coli O157: H7 in feedlot cattle. J Food Prot. 2010; 73(7):1304–12. PMID: 20615343
91. Navaneethan U, Giannella R a. Thinking beyond the colon-small bowel involvement in clostridium difficile infection. Gut Pathog. 2009; 1(1):7. https://doi.org/10.1186/1757-4749-1-7 PMID: 19338685
92. Alhnan MA, Cosi D, Murdan S, Basit AW. Inhibiting the gastric burst release of drugs from enteric microparticles: the influence of drug molecular mass and solubility. J Pharm Sci. 2010; 99(10):4215–27. https://doi.org/10.1002/jps.22138
93. Kietzmann D, Moulari B, Béduneau A, Pellequer Y, Lamprecht A. Colonic delivery of carboxyfluorescein by pH-sensitive microspheres in experimental colitis. Eur J Pharm Biopharm. 2010 Oct; 76(2):290–5. https://doi.org/10.1016/j.ejpb.2010.06.013 PMID: 20600885
94. Wittaya-areekul S, Kruenate J, Prahsarn C. Preparation and in vitro evaluation of mucoadhesive properties of alginate / chitosan microparticles containing prednisolone. Int J Pharm. 2006; 312:113–8. https://doi.org/10.1016/j.ijpharm.2006.01.003 PMID: 16490331
95. Bean JE, Alves DR, Laabei M, Esteban PP, Thet NT, Enright MC, et al. Triggered Release of Bacteriophage K from Agarose / Hyaluronan Hydrogel Matrixes by Staphylococcus aureus Virulence Factors. Chem Mater. 2014; 26:7201–8.
96. Malik DJ, Sokolov IJ, Vinner GK, Mancuso F, Cinquerrui S, Vladisavljevic GT, et al. Formulation, stabili-sation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci [Internet]. 2017; (May):1–34. Available from: http://dx.doi.org/10.1016/j.cis.2017.05.014
97. Gibson PR., Fixa B., Pekarkova B., Batovsky M., Radford-Smith G., Tibitanzl J., et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2006; 23:1017–26. https://doi.org/10.1111/j.1365-2036.2006.02861.x PMID: 16573804